116 Healthcare Stocks Moving In Wednesday's Session

Gainers

Neurotrope, Inc. NTRP stock moved upwards by 133.1% to $3.38 during Wednesday's regular session.

Genprex, Inc. GNPX stock rose 46.8% to $1.69.

Trillium Therapeutics, Inc. TRIL stock surged 28.7% to $3.56.

Aevi Genomic Medicine, Inc. GNMX shares rose 26.8% to $0.24.

Lianluo Smart, Inc. LLIT shares increased by 22.9% to $0.86.

Baudax Bio, Inc. BXRX shares moved upwards by 19.3% to $8.40.

Citius Pharmaceuticals, Inc. CTXR stock rose 16.6% to $1.19.

ArTara Therapeutics, Inc. TARA stock increased by 16.4% to $33.00.

Soleno Therapeutics, Inc. SLNO shares surged 15.2% to $3.86. The most recent rating by Craig-Hallum, on January 10, is at Buy, with a price target of $8.00.

Evelo Biosciences, Inc. EVLO stock rose 14.5% to $5.29.

Tetraphase Pharmaceutical, Inc. TTPH stock moved upwards by 12.2% to $3.32. The most recent rating by Gabelli & Co., on October 31, is at Buy, with a price target of $5.00.

Aethlon Medical, Inc. AEMD shares surged 11.7% to $2.58.

OPKO Health, Inc. OPK shares moved upwards by 11.1% to $1.75. The most recent rating by Piper Jaffray, on November 25, is at Overweight, with a price target of $2.50.

Happiness Biotech, Inc. HAPP stock increased by 10.9% to $4.67.

Akcea Therapeutics, Inc. AKCA shares surged 10.1% to $19.09. The most recent rating by BMO Capital, on November 06, is at Outperform, with a price target of $36.00.

Aptinyx, Inc. APTX stock surged 9.7% to $5.10. The most recent rating by BMO Capital, on November 13, is at Outperform, with a price target of $13.00.

 

Losers

Novavax, Inc. NVAX stock plummeted 19.1% to $7.95 during Wednesday's regular session.

Titan Pharmaceuticals, Inc. TTNP shares fell 13.1% to $0.32.

Sierra Oncology, Inc. SRRA shares fell 11.8% to $0.35. The most recent rating by Oppenheimer, on December 06, is at Outperform, with a price target of $1.20.

Ritter Pharmaceuticals, Inc. RTTR shares fell 11.1% to $0.20.

ImmuCell, Inc. ICCC shares declined 10.8% to $5.28.

Hutchison China Meditech, Inc. HCM shares fell 10.6% to $26.37. According to the most recent rating by CLSA, on November 19, the current rating is at Buy.

Mereo BioPharma Group, Inc. MREO shares decreased by 10.6% to $1.94.

Cleveland BioLabs, Inc. CBLI shares decreased by 10.1% to $1.02.

NeuroMetrix, Inc. NURO shares decreased by 9.8% to $3.95.

Blueprint Medicines, Inc. BPMC shares fell 9.3% to $72.33. The most recent rating by Deutsche Bank, on December 10, is at Hold, with a price target of $70.00.

Valeritas Holdings, Inc. VLRX stock declined 9.3% to $0.72. According to the most recent rating by Oppenheimer, on December 23, the current rating is at Perform.

Organovo Holdings, Inc. ONVO shares fell 9.0% to $0.37.

Cocrystal Pharma, Inc. COCP shares declined 8.6% to $0.68.

Concord Medical Services, Inc. CCM stock declined 8.3% to $2.55.

NantHealth, Inc. NH stock declined 8.2% to $1.34.

Seelos Therapeutics, Inc. SEEL shares fell 8.0% to $1.38. The most recent rating by H.C. Wainwright, on November 18, is at Buy, with a price target of $2.00.

NantKwest, Inc. NK shares decreased by 7.8% to $5.77.

Ra Medical Systems, Inc. RMED shares declined 7.8% to $1.89.

VBI Vaccines, Inc. VBIV stock plummeted 7.5% to $1.53. The most recent rating by Raymond James, on November 14, is at Outperform, with a price target of $3.00.

Iterum Therapeutics, Inc. ITRM stock decreased by 7.5% to $2.72. The most recent rating by RBC Capital, on December 11, is at Outperform, with a price target of $10.00.

Eyegate Pharmaceuticals, Inc. EYEG stock plummeted 7.5% to $6.09.

Cutera, Inc. CUTR shares plummeted 7.4% to $28.74.

Evoke Pharma, Inc. EVOK stock fell 7.3% to $1.41.

PolarityTE, Inc. PTE shares plummeted 7.1% to $3.67. The most recent rating by Piper Jaffray, on November 13, is at Overweight, with a price target of $6.00.

NewLink Genetics, Inc. NLNK shares decreased by 7.1% to $2.10.

Synlogic, Inc. SYBX stock decreased by 6.3% to $2.98.

Adamis Pharmaceuticals, Inc. ADMP stock decreased by 6.3% to $0.72. According to the most recent rating by Raymond James, on November 26, the current rating is at Market Perform.

Dynavax Technologies, Inc. DVAX stock plummeted 6.2% to $5.71.

Evolus, Inc. EOLS shares fell 6.2% to $10.47. The most recent rating by SVB Leerink, on November 26, is at Outperform, with a price target of $25.00.

IMAC Holdings, Inc. IMAC shares plummeted 6.2% to $1.22. According to the most recent rating by Dawson James, on January 14, the current rating is at Neutral.

Strata Skin Sciences, Inc. SSKN shares fell 6.1% to $2.00. The most recent rating by Ladenburg Thalmann, on December 09, is at Buy, with a price target of $5.25.

Seneca Biopharma, Inc. SNCA stock plummeted 5.9% to $1.27.

Biocept, Inc. BIOC shares fell 5.9% to $0.33.

Cellect Biotechnology, Inc. APOP shares decreased by 5.9% to $2.65.

Mallinckrodt, Inc. MNK stock decreased by 5.8% to $5.68.

Avinger, Inc. AVGR shares fell 5.8% to $1.14.

Biolase, Inc. BIOL stock fell 5.8% to $0.82.

Zafgen, Inc. ZFGN stock decreased by 5.5% to $1.20.

Rigel Pharmaceuticals, Inc. RIGL shares declined 5.5% to $2.83. The most recent rating by BMO Capital, on December 09, is at Outperform, with a price target of $8.00.

Obalon Therapeutics, Inc. OBLN shares decreased by 5.5% to $1.91.

Guardion Health Sciences, Inc. GHSI shares fell 5.3% to $0.33.

Aytu BioScience, Inc. AYTU shares fell 5.2% to $0.82.

Fulcrum Therapeutics, Inc. FULC shares decreased by 5.2% to $17.99.

Puma Biotechnology, Inc. PBYI shares decreased by 5.2% to $9.28. The most recent rating by H.C. Wainwright, on December 06, is at Buy, with a price target of $15.00.

Clearside Biomedical, Inc. CLSD stock fell 4.9% to $2.71.

Cerus, Inc. CERS stock plummeted 4.9% to $4.26. According to the most recent rating by BTIG Research, on November 13, the current rating is at Buy.

Zai Lab, Inc. ZLAB shares decreased by 4.9% to $49.60. The most recent rating by Citigroup, on December 30, is at Buy, with a price target of $84.00.

Kezar Life Sciences, Inc. KZR stock declined 4.9% to $3.32.

Sophiris Bio, Inc. SPHS shares declined 4.9% to $0.83.

Inovio Pharmaceuticals, Inc. INO shares declined 4.8% to $3.39. The most recent rating by PiperJaffray, on January 03, is at Overweight, with a price target of $8.00.

Equillium, Inc. EQ shares plummeted 4.8% to $4.20.

Heat Biologics, Inc. HTBX stock fell 4.7% to $0.31.

Psychemedics, Inc. PMD shares plummeted 4.7% to $10.05.

Assertio Therapeutics, Inc. ASRT shares declined 4.6% to $1.24.

Molecular Templates, Inc. MTEM stock fell 4.6% to $13.79.

Precision BioSciences, Inc. DTIL stock decreased by 4.6% to $10.14.

Unity Biotechnology, Inc. UBX stock decreased by 4.5% to $7.04. The most recent rating by Cantor Fitzgerald, on December 12, is at Overweight, with a price target of $20.00.

Orgenesis, Inc. ORGS shares declined 4.5% to $4.86.

InVivo Therapeutics Hldg, Inc. NVIV stock declined 4.5% to $0.32.

Gritstone Oncology, Inc. GRTS shares fell 4.5% to $10.31.

Tyme Technologies, Inc. TYME shares decreased by 4.4% to $1.83.

Syndax Pharmaceuticals, Inc. SNDX shares decreased by 4.4% to $8.27. The most recent rating by H.C. Wainwright, on January 13, is at Buy, with a price target of $17.00.

Precipio, Inc. PRPO shares plummeted 4.4% to $2.19. The most recent rating by Maxim Group, on November 22, is at Buy, with a price target of $4.00.

Avita Medical, Inc. RCEL shares declined 4.3% to $9.52.

Jaguar Health, Inc. JAGX stock declined 4.3% to $0.92. The most recent rating by H.C. Wainwright, on November 18, is at Buy, with a price target of $3.00.

Lexicon Pharmaceuticals, Inc. LXRX shares plummeted 4.3% to $3.88. According to the most recent rating by Gabelli & Co., on December 11, the current rating is at Hold.

TCR2 Therapeutics, Inc. TCRR stock plummeted 4.3% to $13.25. The most recent rating by HC Wainwright & Co., on November 04, is at Buy, with a price target of $19.00.

DBV Technologies, Inc. DBVT stock fell 4.3% to $11.92. The most recent rating by Stifel, on January 09, is at Buy, with a price target of $18.00.

Anavex Life Sciences, Inc. AVXL stock decreased by 4.3% to $3.04.

Neptune Wellness Solns, Inc. NEPT stock decreased by 4.2% to $2.95.

Genocea Biosciences, Inc. GNCA stock decreased by 4.2% to $2.26. According to the most recent rating by SVB Leerink, on November 15, the current rating is at Outperform.

Albireo Pharma, Inc. ALBO shares declined 4.2% to $23.64.

Aravive, Inc. ARAV shares decreased by 4.2% to $11.49. The most recent rating by H.C. Wainwright, on December 20, is at Buy, with a price target of $25.00.

Five Prime Therapeutics, Inc. FPRX shares fell 4.1% to $5.79.

TransMedics Group, Inc. TMDX shares plummeted 4.1% to $19.37. The most recent rating by Cowen & Co., on November 07, is at Outperform, with a price target of $28.00.

Conformis, Inc. CFMS shares plummeted 4.1% to $1.17.

Aridis Pharmaceuticals, Inc. ARDS shares decreased by 4.1% to $7.96. The most recent rating by H.C. Wainwright, on December 30, is at Buy, with a price target of $7.00.

Aclaris Therapeutics, Inc. ACRS shares decreased by 4.0% to $1.66.

Hancock Jaffe, Inc. HJLI stock decreased by 4.0% to $0.57.

ContraFect, Inc. CFRX shares decreased by 4.0% to $1.07.

Cidara Therapeutics, Inc. CDTX shares fell 4.0% to $3.75. The most recent rating by WBB Securities, on December 04, is at Buy, with a price target of $6.25.

Crinetics Pharmaceuticals, Inc. CRNX stock plummeted 4.0% to $22.88. The most recent rating by Roth Capital, on December 23, is at Buy, with a price target of $37.00.

Esperion Therapeutics, Inc. ESPR stock declined 3.8% to $54.06.

CTI BioPharma, Inc. CTIC shares fell 3.8% to $1.29.

Milestone Pharmaceuticals, Inc. MIST shares plummeted 3.8% to $19.06.

Eton Pharmaceuticals, Inc. ETON shares plummeted 3.8% to $7.10.

XTL Biopharmaceuticals, Inc. XTLB shares declined 3.8% to $1.28.

PetMed Express, Inc. PETS stock fell 3.8% to $24.66.

Savara, Inc. SVRA shares fell 3.7% to $3.37.

Cortexyme, Inc. CRTX shares plummeted 3.7% to $56.16.

CHF Solutions, Inc. CHFS stock declined 3.7% to $1.04.

Aquestive Therapeutics, Inc. AQST stock plummeted 3.7% to $3.95. The most recent rating by BMO Capital, on January 13, is at Outperform, with a price target of $18.00.

Spectrum Pharmaceuticals, Inc. SPPI shares plummeted 3.6% to $2.94. The most recent rating by B. Riley FBR, on December 27, is at Buy, with a price target of $11.00.

Celsion, Inc. CLSN stock fell 3.5% to $1.63.

Conatus Pharmaceuticals, Inc. CNAT stock fell 3.5% to $0.43.

Clovis Oncology, Inc. CLVS stock fell 3.5% to $9.02. The most recent rating by Evercore ISI Group, on November 19, is at In-Line, with a price target of $8.00.

Genfit, Inc. GNFT stock decreased by 3.5% to $19.80. The most recent rating by HC Wainwright & Co., on October 31, is at Buy, with a price target of $58.00.

Leap Therapeutics, Inc. LPTX shares plummeted 3.5% to $1.81. The most recent rating by Raymond James, on January 08, is at Outperform, with a price target of $2.50.

Streamline Health Solns, Inc. STRM shares fell 3.4% to $1.26.

Hepion Pharmaceuticals, Inc. HEPA shares declined 3.4% to $5.35. The most recent rating by Brookline Capital, on November 22, is at Buy, with a price target of $12.00.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Intraday UpdateMarketsMoversTrading Ideashealthcare stocksTop Gainers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!